6160.HK - BeiGene, Ltd.

HKSE - HKSE Delayed Price. Currency in HKD

BeiGene, Ltd.

94 Solaris Avenue
Camana Bay
Grand Cayman KY1-1108
Cayman Islands


Full Time Employees9,400

Key Executives

NameTitlePayExercisedYear Born
Mr. John V. OylerCo-Founder, Exec. Chairman & CEO2.05MN/A1968
Dr. Xiaobin Wu Ph.D.Pres, COO & GM of China1.69MN/A1962
Dr. Xiaodong Wang Ph.D.Co- Chairman of Scientific Advisory Board & Non-Exec. Director Co-Founder250kN/A1963
Ms. Julia WangCFO & Principal Accounting Officer964.2kN/A1972
Mr. Wang LaiGlobal Head of R&D996.92k9.13M1977
Mr. Kevin C. MannixSr. VP of Investor Relations.N/AN/AN/A
Mr. Chan LeeGen. Counsel & Sr. VPN/AN/AN/A
Dr. Yan QiSr. VP & Head of Public Affairs - Greater ChinaN/AN/AN/A
Mr. Jason W. RadfordSr. VP of Strategy & Corp. Devel.N/AN/A1982
Dr. Mark LanasaSr. VP & Chief Medical Officer for Solid TumorsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.


BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Enlivex Therapeutics Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Corporate Governance

BeiGene, Ltd.’s ISS Governance QualityScore as of June 1, 2023 is 6. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.